Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment

Table 2 Univariate analysis for OS, LCR and PFS

	n	OS			LCR			PFS
	n	MST (months)	3-year (%)	p	MST (months)	3-year (%)	p	MST (months)	3-year (%)	p
Histopathology
SCC	40	35	48.9		–	58.4		10	31.3
The others	10	25	40	0.351	16	46.9	0.446	14	25	0.849
Initial FIGO
I	11	33	37.9		–	25		8	9.1
II	24	48	56.9		–	62.9		13	38.6
III	10	35	42		–	63.5		13	20.8
IV	5	33	26.7	0.481	–	100	0.184	–	66.7	0.24
Initial treatment
Surgery with PORT	23	33	44.1		13	38.2		8	13.6
Surgery without PORT	5	–	60		–	75		–	60
CCRT	17	35	47.9		–	80.8		15	40.7
RT alone	5	12	40	0.383	9	50	0.131	9	50	0.154
Age at the recurrence
> 57	25	48	59.4		–	68.8		20	43.6
≦57	25	25	35.3	0.152	17	45.1	0.14	7	18.3	0.031
Serum SCC-Ag at the recurrence
Positive	26	31	38.8		13	37.2		7	13.3
Negative	17	50	61.1	0.158	–	86.7	0.012	–	53.6	0.002
Serum CEA at the recurrence
Positive	17	30	41.2		13	40.2		7	12.5
Negative	26	48	51.9	0.227	–	66.1	0.081	17	45	0.070
Time to recurrence
> 10	24	48	57.6		–	61.1		14	34.6
≦10	26	33	38.1	0.498	–	51.8	0.404	9	24.1	0.281
Maximum size of PALN recurrence
> 17 mm	21	23	38.3		13	46.6		5	25.3
≦17 mm	29	42	53	0.587	–	62.6	0.237	15	33.2	0.078
Number of PALN recurrence
1–2	24	48	55.3		9	82		16	44.5
3 and more	26	30	38.8	0.244	–	36.1	0.001	7	16.5	0.009
Treatment for PALN recurrence
RT alone	18	30	41.3		–	55.5		9	14.1
CCRT	7	–	85.7		–	100		–	71.4
Surgery	3	–	66.7		–	100		–	66.7
Chemotherapy	17	31	48.8		–	33.6	0.025	8	13.7	0.059
BSC	5	12	0	0.014

Abbreviations: OS Overall survival, LCR Local control rate, PFS Progression free survival, MST Median survival time, SCC Squamous cell carcinoma antigen, FIGO International Federation of Gynecology and Obstetrics, PORT Post-operative radiation therapy, serum SCC-Ag Serum squamous cell carcinoma antigen, serum CEA Serum carcinoembryonic antigen, CCRT Concurrent chemoradiation therapy, RT Radiation therapy, PALN Para-aortic lymph nodes, BSC Best supportive care

ISSN: 1748-717X